A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as ...

Similar 3-year metastasis-free survival, fewer hot flashes, more gynecomastia ...

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...

Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...

The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...

With the removal of FDA warning labels, hormone therapy to treat symptoms of menopause has grown in popularity. Now some patients are reporting delays in filling prescriptions for estrogen patches.

Bethesda, MD - In a head-to-head crossover comparison, oral estrogen therapy (ET) was associated with a sustained increase in the inflammatory marker C-reactive protein (CRP) among postmenopausal ...

The nationwide shortage is being driven by a steady rise in demand for menopausal hormone therapy that is outpacing current patch supply.

Add Yahoo as a preferred source to see more of our stories on Google. (Getty Images) One of the most commonly used forms of menopause hormone therapy is hard to find right now. This applies to ...